of 1 of these steps could have a negative effect on the clinical outcome. Sometimes, the delay is caused by something that we cannot control, as in the late antiplatelet effects of oral P2Y 12 Nevertheless, a major Achilles' heel of this treatment is that it provides an effective platelet inhibition 2 h after the loading dose (LD) in one-half of patients, and at least 4 h are required to achieve an effective platelet inhibition in the majority of patients (6) . Therefore, several strategies have attempted to increase the drug absorption and speed up the onset of action, ranging from a double dose (1,7,8) to a different type of administration (9, 10) . The MOJITO (Mashed Or Just Integral pill of TicagrelOr) study (9) for the first time demonstrated the superiority of ticagrelor crushed pills compared with whole tablets in terms of earlier platelet inhibition. Importantly, the LD of prasugrel was administered immediately after removal of the guiding catheter, and a post hoc analysis of morphine use was conducted according with the finding of an association between use of morphine and HPR (12) . A significant reduction in PRU with crushed compared with whole tablets was found at 2 h (primary endpoint), and this significant difference was already evident at 30 min and 1 h, even among patients receiving morphine; moreover, at these 2 time points, the mean PRU in the whole group was >208, reflecting an HPR maintained relevant to the contents of this paper to disclose. showed a reduction of percutaneous coronary intervention periprocedural thrombotic complications.
Cangrelor is indeed an effective antiplatelet drug, but in this study: it was tested just against clopidogrel therapy; the rate of STEMI was 11.6%; the risk of bleeding increased; and last but not least, its availability and costs compared with a loading dose of an oral antiplatelet drug raise some concerns. The rate of stent thrombosis #24 h is 2.1% even with ticagrelor and prasugrel utilization (15); hence, every adjunctive strategy or technique must be used to move faster and safer in STEMI patients with no fear to crush. 
